Achieve Life Sciences, Inc. Overview
Pro stress-test →Achieve Life Sciences is a late-stage pharmaceutical company developing cytisinicline, a plant-based alkaloid that reduces nicotine withdrawal symptoms, for nicotine independence. The company is pursuing a landmark regulatory opportunity with an FDA NDA acceptance with PDUFA date set for June 20, 2026, positioning it to potentially deliver the first new smoking cessation therapy in nearly two decades.
Strategic Profile
Pro stress-test →The company focuses on addressing the global smoking and nicotine dependence epidemic through cytisinicline, having completed two Phase III studies for smoking cessation and one Phase II study for vaping cessation. Achieve maintains license and supply agreements with Sopharma AD and University of Bristol, establishing strategic partnerships for development and commercialization.
Competitive Landscape
Pro stress-test →Achieve competes in the smoking cessation market dominated by established therapies including Chantix (varenicline), nicotine replacement therapies, and behavioral interventions. The company's primary competitive advantage is cytisinicline's novel mechanism as a potential first new chemical entity in two decades, though it faces entrenched market competition and behavioral switching costs. Barriers to entry in smoking cessation are moderate given regulatory pathways and established prescriber relationships.
Industry Context
Achieve Life Sciences, Inc. operates in Specialty Pharmaceuticals / Smoking Cessation Therapeutics.
Key facts
Headquarters: Seattle, Washington